ORXOF (Orexo AB) Median PS Value: $1.27 (As of Jun. 24, 2026) — 76% Above Median


ORXOF Orexo AB ORXOF
34 GF Score
Price $2.10
GF Value $0.68
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Orexo AB Median PS Value?

Orexo AB ORXOF 34 Median PS Value is $1.27 as of Jun. 24, 2026, which is 76% above its 10-year median of 0.72. GuruFocus rates ORXOF with a GF Score™ of 34/100 and a GF Value™ of $0.68 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 544 Drug Manufacturers companies, Orexo AB ranks worse than 89.15% on this metric.

This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Orexo AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.655. Orexo AB's 10-Year median PS Ratio is 1.9389. Therefore, the Median PS Value for today is $1.27.

As of today (2026-06-24), Orexo AB's share price is $2.10. Orexo AB's Median PS Value is $1.27. Therefore, Orexo AB's Price to Median PS Value for today is 1.65.

The historical rank and industry rank for Orexo AB's Median PS Value or its related term are showing as below:

ORXOF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.24   Med: 0.72   Max: 2.45
Current: 1.65

During the past 13 years, the highest Price to Median PS Value of Orexo AB was 2.45. The lowest was 0.24. And the median was 0.72.

ORXOF's Price-to-Median-PS-Value is ranked worse than
89.15% of 544 companies
in the Drug Manufacturers industry
Industry Median: 0.85 vs ORXOF: 1.65

Orexo AB  (OTCPK:ORXOF) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Orexo AB's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=2.10/1.27
=1.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Orexo AB Median PS Value Related Terms


Orexo AB Median PS Value Historical Data

* Premium members only.

The historical data trend for Orexo AB's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orexo AB Median PS Value Chart

Orexo AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.58 4.08 3.27 1.66 1.42

Orexo AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.39 0.80 1.18 1.42 1.33

ORXOF vs ZTS: Median PS Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Orexo AB's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orexo AB Price-to-Median-PS-Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orexo AB's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Orexo AB's Price-to-Median-PS-Value falls into.


ORXOF
34GF Score
Orexo AB ORXOF
Median PS Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orexo AB Median PS Value Calculation

Orexo AB's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=0.655*1.9389
=1.27

10-Year Median PS Ratio is 1.9389.
Orexo AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.655.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Median PS Value →
What does a Median PS Value of $1.27 mean?
Orexo AB (ORXOF) has a Median PS Value of $1.27 as of Jun. 24, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Orexo AB and its competitors. This is 76% above median its historical median of 0.72. Over the past decade, Orexo AB's Median PS Value has ranged from 0.24 to 2.45. According to the industry distribution chart, Orexo AB ranks #485 out of 544 companies in the Drug Manufacturers industry, placing it in the top 89.2%.
Is Orexo AB's Median PS Value too high?
Orexo AB's current Median PS Value of $1.27 is 76% above median its 10-year median of 0.72. Over the past 10 years, this metric has ranged from a low of 0.24 to a high of 2.45. The Drug Manufacturers industry median Median PS Value is 0.85. Orexo AB's value of $1.27 is 49.4% above this industry median. Based on the distribution chart, Orexo AB ranks #485 out of 544 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Orexo AB has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orexo AB's Median PS Value compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Orexo AB ranks #485 out of 544 companies for Median PS Value. This places Orexo AB in the lower half of its industry. The industry median Median PS Value is 0.85. Orexo AB's value of $1.27 is 49.4% above this benchmark. Historically, Orexo AB's own Median PS Value has ranged from 0.24 to 2.45 over the past decade. While the company's 10-year median is 0.72 vs. the industry median of 0.85, Orexo AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Drug Manufacturers company?
The median Median PS Value among Drug Manufacturers companies is 0.85, based on 544 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orexo AB's current Median PS Value of $1.27 is 49.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Orexo AB and its competitors. For the Drug Manufacturers industry, the median Median PS Value is 0.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orexo AB's current Median PS Value is $1.27, which is 76% above median its own 10-year median of 0.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orexo AB stock overvalued right now?
Based on GuruFocus' analysis, Orexo AB (ORXOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.68, compared to a current price of $2.10 — trading 208.8% above its estimated fair value. The current Median PS Value is $1.27, which is 76% above median its 10-year median of 0.72 and 49.4% above the Drug Manufacturers industry median of 0.85. Orexo AB's overall GF Score™ is 34/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Orexo AB (ORXOF), the current Median PS Value is $1.27 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orexo AB (ORXOF) Overvalued in 2026?

Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued. The current stock price of $2.10 is trading 208.8% above its estimated GF Value™ of $0.68. GuruFocus considers Orexo AB to be Significantly Overvalued.

Key valuation signals for ORXOF:

  • Median PS Value: $1.27 (76% above median its 10-year median of 0.72)
  • GF Value™: $0.68 vs. price of $2.10 (208.8% above fair value)
  • GF Score™: 34/100 with 7 warning signs
  • Industry Position: 49.4% above the Drug Manufacturers median (#485 of 544)

No single metric tells the full story. See the ORXOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Orexo AB Business Description

Address Virdings alle 22, Uppsala, SWE, 75105
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
34GF Score

Get the complete analysis for ORXOF

Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.10
Price
$0.68
GF Value